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Objective.Toquantifythebeneﬁtsinsurvivalandqualityoflifeinpatientsreceivingbevacizumab(BEV)forrecurrentglioblastoma
(GBM). Methods. This is a retrospective study of 40 adult patients with recurrent GBM treated between 2005 and 2009 at a single
institution. All patients had initial treatment with surgery, radiation, and concurrent temozolomide, then monthly temozolomide.
Over 250 charts were screened. Suﬃcient data was available for 20 patients treated with BEV and 20 patients who did not receive
BEV at the time of recurrence. The independent living score (ILS), designed to reward long-term independent survival, was
calculated for each patient. Results. The mean ILS was nearly double in the BEV group compared to the No-BEV group (15.0
versus 8.2, P = 0.002, t-test). Two months after initiation of therapy, the median steroid dose dropped by over 90% in patients
treated with BEV, but doubled in the NoBEV group. Median survival from the time of recurrence was signiﬁcantly aﬀected: 10.6
months in the BEV group versus 4.2 months (P<0.001, log rank survival) in the NoBEV group. Conclusions. BEV increases
independent living and lengthens overall survival after GBM recurrence. Reduction in steroid dose may contribute to prolonged
independence.
1.Introduction
In May of 2009, the FDA approved the use of bevacizumab
(BEV) for recurrent glioblastoma (GBM) based on imaging
and clinical responses demonstrated in Phase II clinical
trials [1–6]. Many centers, particularly in the USA, have
rapidly adopted bevacizumab into regular clinical practice,
though there is no phase III evidence of its eﬃcacy. Some
propose that the FDA rescinds approval for BEV if current
randomized studies do not show eﬃcacy [7–10]. Others
strongly believe that it is an eﬀective, potent drug despite the
modest response rate and eﬀect on progression-free survival
demonstrated in previous trials. We hypothesized that BEV
bothlengthenspatientsurvivalandimproves“qualityoflife,”
which is diﬃcult to study clinically.
Several years ago, we proposed an Independent Living
Score (ILS) in which the patient’s capacity to remain
independent is used as a global measure of quality of life
[11]. The ILS is based on the Karnofsky performance score
and is weighted to increase the score of patients who retain
independence later in their course. We tested our hypothesis
that patients who receive BEV live longer and remain
independent longer than those who do not receive BEV,
by comparing a cohort of patients who received BEV with
a contemporaneous cohort whose members, for insurance
reasons, did not receive BEV, using overall survival and ILS
as endpoints. In many cases, patients with public insurance
received BEV after appeal, while private insurers declined to
cover BEV prior to FDA approval.
2. Methods
Permission was granted from Stanford’s IRB to perform this
study. Patients were identiﬁed from the senior author’s (L.
Recht) personal database that tracks all patients at Stanford
Medical Center with primary brain tumors. Hospital charts
were screened to identify adult patients (age >18) fulﬁlling
the following requirements: (i) diagnosis of glioblastoma
or gliosarcoma without prior diagnosis of lower grade2 Chemotherapy Research and Practice
Table 1: Assignment of the independence score based on Karnofsky performance score.
Score (%) Criteria Independence score
100 Normal. No complaints or evidence of disease.
Able to carry on near-normal activity and to work; no
special care needed.
Independence Score: 2
90 Able to carry on activity, minor signs of disease.
80 Normal activity with eﬀort, some signs of disease.
70 Cares for self. Unable to carry on normal activity or
active work.
60 Requires occasional assistance, but cares for personal
needs.
U n a b l et ow o r k ;a b l et ol i v ea th o m ea n dc a r ef o rm o s t
personal needs; varying amount of assistance needed.
Independence Score: 1 50 Requires considerable assistance and medical care.
40 Disabled. Requires special care and assistance.
Unable to care for self; requires equivalent of
institutional or hospital care; disease may be
progressing rapidly.
Independence Score: 0
30 Severely disabled. Hospitalization needed, but death
not imminent.
20 Very sick. Hospital admission needed. Active
supportive care.
10 Moribund. Fatal process rapidly progressing
0D e a d
Table 2: Demographics of patient cohorts.
No bevacizumab Bevacizumab Statistical signiﬁcance of diﬀerences
Histology GBM 20 GBM 19 Not signiﬁcant
Gliosarcoma 1
Age (years) 55 ± 9.3 58.7 ± 10.7 Not signiﬁcant
Initial KPS 70 (60–80) 75 (65–85) Not signiﬁcant
Time to ﬁrst recurrence (months) 9.25 ± 4.7 10.5 ± 4.8 Not signiﬁcant
Mean time to diagnosis (from 1/1/05) 25.9 ± 14.1 36.7 ± 8.8 P<0.01
glioma; (ii) upfront treatment with six weeks of concurrent
radiotherapy and temozolomide; (iii) MRI evidence of
tumorrecurrence;(iv)atleastthreeStanfordencountersover
the patient’s course; (v) recording of KPS at each visit; (vi)
administration of at least one IV infusion of bevacizumab
(BEV group). More than 200 charts were screened. Twenty
patients meeting these criteria were identiﬁed. Our intention
was to create a control group 2-3 times larger than the
BEV group, but suﬃcient data was available for only twenty
patients meeting all criteria except vi (No-BEV group).
All BEV patients were treated with the same regimen of
BEV 7.5–10mg/kg every two weeks for three infusions fol-
lowed by continued infusions at three-week intervals. Seven
patients initially received BEV alone; 13 others received BEV
initiallyincombinationwithotherchemotherapeuticagents:
irinotecan (n = 6), lomustine (n = 4), and temozolomide
(n = 3) or no additional therapy (n = 7). Patients in the
N o - B E Vg r o u pr e c e i v e dl o m u s t i n e( n = 4), lomustine with
erlotinib (n = 1), BCNU (n = 1), temozolomide (n = 2),
short-course additional radiation with temozolomide (n =
1), cyclophosphamide with erlotinib (n = 1), reoperation
followed by BCNU (n = 1), experimental chemotherapy
(n = 1), or no additional therapy at the time of recurrence
(n = 8).
Imaging, pathology reports, and clinic notes were
reviewed for all patients. All 40 patients were seen by one
physician (L. Recht). The KPS, assigned at the time of visit,
not retrospectively, was recorded. The ILS was calculated as
described by Recht et al. [11] (example calculations available
in the appendix of Recht’s paper). Patients received 2 points
for KPS ≥ 70, 1 point for KPS ≥ 60, and no points for
a score of 50 or less. In cases where more than one KPS
was available in a month, the lower of the two point scores
was used to calculate ILS (see Table 1). The point score for
each month was then multiplied by a factor emphasizing
independence late in a patient’s course: the number of
months since diagnosis divided by the overall survival. These
weighted monthly point scores were then summed to yield
anindividualpatient’sILS.ModiﬁedMacdonaldcriteria[12]
deﬁned initial recurrence. The determination of progression
despite BEV was made according to RANO working group
criteria [13] of MRI and clinical ﬁndings. Statistical analysis
was performed using a SigmaStat package.
3. Results
Prior to disease recurrence, the two groups were comparable
intermsofage,initialKPS,treatment,andtimetorecurrence
(Table 2). All patients were diagnosed in the interval between
2005 and 2009. Considering 1/1/2005 as time 0, there was a
statistically signiﬁcant diﬀerence between BEV and No-BEV
groups in terms of the dates of diagnosis (36 ± 8.7 versus
26.0±14.1monthsafter1/1/2005,P<0.01,t-test)(Figure 1).Chemotherapy Research and Practice 3
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Figure 1: Month of diagnosis of patient cohorts. Time line of
patient accrual to BEV and No-BEV groups as a function of
month of GBM diagnosis. Dot plot indicates month of diagnosis.
Using 1/1/2005 as Time 0, there is a statistically but not clinically
signiﬁcant diﬀerence in dates of diagnosis.
However, this was unlikely to be clinically signiﬁcant. The
mean times of diagnosis for the BEV and No-BEV groups
were December 2009 and February 2009, respectively. This
10-month diﬀerence in diagnosis date likely altered clinical
care only in respect to use of BEV, which became universally
available to patients with recurrent GBM in May 2009.
BEV patients received a mean of 10.1 ± 4.8 infu-
sions (range: 2–20). Complications deﬁnitely or probably
attributable to BEV occurred in eight patients (40%) and
included DVT (2, both grade 3), asymptomatic grade 1
intracranial hemorrhage (2), grade 1 hypertension, diver-
ticulitis leading to death (grade 4), a grade 2 wound-
healing problem, and grade 2 allergy (1 each). One of
the two patients with steroid myopathy (causing diﬃculty
walking unassisted) prior to BEV regained full strength after
initiation of BEV and reduction of steroid.
Six patients (30%) in the No-BEV group had compli-
cations: DVT (1), pulmonary embolism that ultimately led
to death (1), steroid myopathy (3), cytomegalovirus sepsis
leading to death in a patient on high-dose dexamethasone
alone (1), myelosuppression in patients on high-dose dex-
amethasone alone (2), and myelosuppression in patients on
other chemotherapy (1).
Using conventional measures, the PFS6 for the BEV
treated groups was 45% and the mean PFS was 5.25 ±
3.3 months. This does not signiﬁcantly diﬀer from the
survivalpostrecurrenceoftheNo-BEVcohort(PFS3.95±2.7
months, P, NS, t-test). However, using more global outcome
scales, the administration of BEV resulted in a signiﬁcant
improvement in outcome, including a robust increase in
both total median survival [22.7 (19.3–26.1, 95% CI) versus
13.2 (10.6–15.8) months, P<0.001, log rank survival] and
median survival from time of recurrence [10.6 (8.9–12.3)
versus 4.2 (3.0–5.3) months, P<0.001, log rank survival]
(Figure 2).
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Figure 2: BEV increases survival when administered to patients
with recurrent GBM. (a) Overall survival. (b) Survival after
recurrence. BEV (solid line), No-BEV (dotted line).
To reﬂect overall quality of life, we utilized the indepen-
dent living score (ILS), which quantiﬁes patient indepen-
dence and has been validated in a GBM-aﬄicted population.
The scale is weighted to reward sustained independence and
penalize prolonged periods of nonindependence (for more
details, see Recht et al. [11]). Using this measure, we noted
a marked superiority in ILS for the BEV group relative
to the No-BEV group (15.0 ± 6.5v e r s u s8 . 2± 6.0, P =
0.002, t-test) (Figure 4). Longer survival in the BEV group4 Chemotherapy Research and Practice
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Figure 3: Impact of BEV on steroid requirement. Steroid dose
is markedly decreased after BEV administration. Paired doses of
dexamethasone at initiation and two months after initiation of
BEV or recurrence in the No-BEV group demonstrate a marked
diﬀerence in ability to reduce steroid dosage.
was accompanied by robust improvement in ILS, indicating
that the survival of these patients was marked by retained
independence.
The administration of BEV also dramatically decreased
steroid usage. While median dexamethasone dose was not
signiﬁcantly diﬀerent between the two groups at the time
of recurrence (6mgs versus 4mgs, BEV versus No-BEV, P,
NS), by two months after the initiation of BEV infusions, the
median dexamethasone dose had decreased to 0.4mgs in the
BEV
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Figure 4: Impact of BEV in the independent living score. Time
of functional independence is increased after BEV. The mean
Independent Living Score (ILS) in patients treated with BEV
compared to those in the No-BEV group is nearly double. Results
are depicted as mean ± SD.
BEV group. At the corresponding time point in the No-BEV
group, it had increased to 8mgs (P<0.001, rank sum test)
(Figure 3).
4. Discussion
Unlike other expensive, approved therapies, such as the
carmustinepolymerwafer(Gliadel)[14],theintroductionof
BEVhasdramaticallychangedpracticepatternsintheUnited
States, even in the absence of Phase III evidence. Physicians
who use BEV believe it to be eﬀective and useful. However,
BEV’s complication rates, its tendency to produce tumor
dispersion/invasion [15–17], poor patient survival after
progression of BEV-treated tumors [18], and BEV’s minimal
impact on standard surrogate markers of GBM outcome,
such as PFS [3–5, 15, 19, 20], support the counterargument
that BEV’s overall beneﬁt does not justify its routine use.
Our data demonstrate a robust improvement in patient
independence, in combination with an increase in overall
survival,inpatientswhoreceiveBEV.Thesedatahelpexplain
the enthusiasm for BEV despite unimpressive clinical trial
data. Using surrogate markers such as PFS, we observed
a PFS6 and median duration of survival similar to those
reported in the literature [3–5, 15, 19–24]. However, even
with a BEV complication rate of 40%, there is a dramatic
shift in the entire survival curve “to the right,” with a
survival advantage for BEV-treated patients approaching
9 months from time of recurrence (a duration exceeding
150% of that experienced by patients not receiving BEV).
This improvement in survival duration is accompanied by
a dramatic increase in quality of life, at least as measured
in regard to the very important consideration of maintained
patient independence.
There are several implications of our results. First, the
eﬀect of BEV is fundamentally diﬀerent from that of other
standard antiglioma treatments. There is an extremely highChemotherapy Research and Practice 5
rate of clinical response when using ILS and overall survival
as endpoints, rather than PFS or PFS6. Additionally, there
is an impressive increase in area under the survival curve
after recurrence, which means that the bulk of patients
receiving BEV are getting a survival beneﬁt of 5-6 months.
In contrast, the EORTC study that added temozolomide to
radiation therapy increased the median overall survival only
a modest 6 weeks and was universally adopted primarily
because of its “tail” eﬀect: an increase in the number of
long-term 2-year survivors from 8 to 26% [25]. Our results
with BEV (Figure 2), which seem to be in general agreement
with the observations of others, do not demonstrate this
“tail” eﬀect. Patients are still dying within the expected time
range. However, almost all patients live longer. Few patients
have dramatically lengthened survivals on BEV and none are
“cured.”
The high ILS scores also imply that the time gained with
BEV is of high quality. We believe that this is an important
aspect of the “Avastin eﬀect” which has, paradoxically, both
confounded analysis and motivated clinicians to use it.
Measures such as PFS and PFS6 inadequately assess BEV’s
eﬀect because patients often remain clinically stable despite
tumor progression on MRI. We believe that the quality of a
patient’s survival is often a more meaningful measure of the
success of a therapy than is MRI. Functional independence
is both strongly inﬂuenced by BEV and highly valued by our
patients and their families.
This improvement in quality of life with BEV may
be predominantly attributable to the reduction of steroid
dose it permits. For over 50 years, steroids, primarily
dexamethasone, have been used routinely to treat peritu-
moral brain edema [26]. Although they are highly eﬀective
against chronic edema, steroids given for prolonged periods
producemanysideeﬀects,includingmyopathy,diabetes,and
infection, which can markedly diminish a patient’s quality of
lifeanddurationofsurvival.Thus,standardpracticeistouse
as low a dose as possible.
Although not initially recognized, one of the most
compelling beneﬁts of BEV administration is its reduction
of peritumoral edema and the need for steroids. While this
statement echoes the criticism that the majority of BEV’s
clinical eﬀect is that of a “very powerful steroid” [17, 27–29],
our observations suggest that this should not be interpreted
unfavorably. The average addition of over seven months of
high-quality survival after GBM recurrence, compares well
with that achieved with any cytotoxic agent.
The retrospective nature and lack of a control group
at least double the size of the index cohort are major
limitations of this study. However, several aspects of this
study help control for unintentional biases. The two patient
cohorts were not intentionally case matched, but they are
well balanced in terms of histology, age, KPS, time to ﬁrst
recurrence, and the use of additional chemotherapy at the
time of recurrence. All patients were accrued in the “modern
era” of GBM therapeutics, after the universal adoption of
concurrent upfront radiation with temozolomide [25], with
only a 10-month diﬀerence in the mean date of diagnoses
betweenthetwogroups.WiththeexceptionofBEVapproval,
there were no changes in clinical practice during this time,
implying that the primary diﬀerence in treatment received
by these two groups was insurance approval of BEV. Many
of our public health program patients had access to BEV in
advance of privately insured patients. Thus, the confounding
of conclusion by historical control comparisons [30]w a s
limited in this study.
This study further supports the use of BEV in patients
with recurrent GBM, not only for prolongation of survival,
but maintenance of independence, as well. Our data shed
no light on the most advantageous timing of initiating
BEV, a question that is currently being addressed in Phase
III studies. However, our data do suggest that the use of
traditional radiologic endpoints in trials for recurrent GBM
may underestimate the eﬀects of experimental agents.
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